Study guide
8.1 Inotropes, Vasopressors & Inodilators
AACN Cardiac Medicine Certification CMC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview and the CMC Test Plan
1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them
2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease
2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy
3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease
3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup
4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions
4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation
5 Chapter 5: Vascular Conditions and Vascular Interventions
5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications
6 Chapter 6: Shock States and Mechanical Circulatory Support
6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD
7 Chapter 7: Cardiac Procedures and Structural Heart Interventions
7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications
8 Chapter 8: Cardiovascular Pharmacology
8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure
9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary
9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients
10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral
10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients
11 Chapter 11: Monitoring and Diagnostics
11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography
12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions
12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease
8.1 Inotropes, Vasopressors & Inodilators
Key Takeaways Explain This Topic AI
Vasoactive agents act on specific adrenergic (Alpha-1, Beta-1, Beta-2), dopaminergic (DA1), and vasopressinergic (V1a) receptors to modulate vascular tone, myocardial contractility, heart rate, and organ perfusion.
Norepinephrine is the first-line vasopressor in septic and cardiogenic shock with vasodilatory components, utilizing potent Alpha-1 vasoconstriction with moderate Beta-1 inotropic support to maintain mean arterial pressure.
Dobutamine (Beta-1 inotrope with mild Beta-2 vasodilation) and Milrinone (PDE-3 inhibitor inodilator) enhance cardiac output and reduce ventricular filling pressures; Milrinone acts independently of adrenergic receptors but requires dosage adjustment in renal impairment due to its 2.5-hour elimination half-life, which lengthens to 4–6 hours in renal impairment.
Vasopressin acts as a non-adrenergic vasopressor via V1a vascular receptors, offering crucial pressor synergy in refractory shock and vasoplegic syndrome without exacerbating tachyarrhythmias.
Inotrope and vasopressor extravasation triggers severe Alpha-1 mediated peripheral vasoconstriction and tissue necrosis; emergency management requires immediate infusion cessation, aspiration, and local subcutaneous infiltration of Phentolamine.
Last updated: August 2026
Adrenergic and Non-Adrenergic Receptor Physiology
Inotropic, vasopressor, and inodilator therapies represent essential pharmacologic interventions in the Cardiac Intensive Care Unit (CICU) for restoring organ perfusion, augmenting cardiac output, and normalizing systemic vascular resistance. Safe and effective clinical titration requires a thorough understanding of signal transduction pathways, receptor distribution, and cellular responses across the cardiovascular system.
Vascular and Cardiac Adrenergic Receptor Cascades
Alpha-1 (α₁) Adrenergic Receptors: Located predominantly on vascular smooth muscle of peripheral resistance arterioles and venous capacitance vessels. α₁ receptors couple to the Gq protein subunit, activating phospholipase C (PLC). PLC cleaves phosphatidylinositol 4,5-bisphosphate (PIP₂) into inositol trisphosphate (IP₃) and diacylglycerol (DAG). IP₃ triggers calcium release from the sarcoplasmic reticulum, raising intracellular free calcium ([Ca²⁺]i) and stimulating vascular smooth muscle contraction. This results in arterial vasoconstriction, elevated Systemic Vascular Resistance (SVR), increased Pulmonary Vascular Resistance (PVR), elevated Mean Arterial Pressure (MAP), and enhanced venous return (preload).
Beta-1 (beta₁) Adrenergic Receptors: Concentrated in cardiac tissue, including the sinuatrial (SA) node, atrioventricular (AV) node, and atrial/ventricular cardiomyocytes. beta₁ receptors couple to the Gₛ protein subunit, activating adenylyl cyclase to convert adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP). Rising cAMP levels activate Protein Kinase A (PKA), which phosphorylates L-type calcium channels, ryanodine receptors, and phospholamban. The clinical result encompasses positive inotropy (contractility), positive chronotropy (heart rate), positive dromotropy (AV conduction velocity), and positive bathmotropy (excitability), leading to increased Cardiac Output (CO), Stroke Volume (SV), and Myocardial Oxygen Demand (MVO₂).
Beta-2 (beta₂) Adrenergic Receptors: Located on vascular smooth muscle supplying skeletal muscle, coronary circulation, splanchnic beds, and bronchial smooth muscle. Coupled to Gₛ proteins, beta₂ stimulation elevates intracellular cAMP in smooth muscle cells, triggering PKA-mediated phosphorylation of myosin light-chain kinase (MLCK). Deactivation of MLCK promotes vascular and bronchial smooth muscle relaxation, yielding systemic and coronary vasodilation (decreased SVR) and bronchodilation.
Vasopressin (V₁ₐ) Receptors: Non-adrenergic receptors expressed on vascular smooth muscle cells. V₁ₐ engagement operates through Gq-protein phospholipase C signaling, mobilizing intracellular calcium to produce profound vasoconstriction. V₁ₐ signaling remains fully active during severe lactic acidosis and hypoxia, states in which adrenergic receptors undergo desensitization and uncoupling.
Dopaminergic (DA₁) Receptors: Located in renal, mesenteric, coronary, and cerebral vascular beds. Coupled to Gₛ proteins, DA₁ activation stimulates adenylyl cyclase to raise cAMP, causing vascular smooth muscle relaxation and selective renal and splanchnic vasodilation at low infusion concentrations.
Receptor Target Matrix for Vasoactive Support
Receptor Target Primary Signal Transduction Cardiovascular & Tissue Location Physiological & Hemodynamic Response Clinical Indications & Manifestations
α₁ Adrenergic Gq → PLC → IP₃ / DAG → ↑ [Ca²⁺]i Arteriolar & venous smooth muscle Arterial vasoconstriction, ↑ SVR, ↑ PVR, ↑ MAP, ↑ Preload Vasodilatory shock, septic shock, neurogenic shock, persistent hypotension
beta₁ Adrenergic Gₛ → Adenylyl Cyclase → ↑ cAMP → PKA SA node, AV node, myocardium ↑ Contractility, ↑ Heart Rate, ↑ AV conduction, ↑ Stroke Volume Cardiogenic shock, decompensated heart failure, bradycardia, low cardiac output
beta₂ Adrenergic Gₛ → Adenylyl Cyclase → ↑ cAMP → MLCK Inhibition Vascular & bronchial smooth muscle Arterial vasodilation, ↓ SVR, bronchodilation, mild coronary dilation Bronchospasm, mild afterload reduction, peripheral vasodilation
V₁ₐ Vasopressin Gq → PLC → ↑ [Ca²⁺]i (Non-Adrenergic) Vascular smooth muscle, efferent renal arterioles Non-adrenergic vasoconstriction, ↑ MAP, constricts efferent renal arterioles Vasoplegic shock, refractory septic shock, cardiac arrest, post-CPB vasoplegia
DA₁ Dopaminergic Gₛ → Adenylyl Cyclase → ↑ cAMP Renal, splanchnic, mesenteric, cerebral beds Renal & splanchnic vasodilation, ↑ Renal blood flow (at low infusion rates) Historical renal perfusion (no longer recommended as routine prophylaxis)
Loading diagram... Pharmacological Classification of Vasoactive and Inotropic Agents
- Clinical Pharmacology of Inotropes, Vasopressors & Inodilators
- 1. Norepinephrine (Levophed)
Mechanism of Action: Direct-acting sympathomimetic amine with potent α₁-adrenergic receptor agonist activity combined with modest beta₁-adrenergic agonist activity (α₁ gg beta₁).
Clinical Indications: First-line vasopressor for septic shock, distributive shock, and cardiogenic shock presenting with severe hypotension (MAP <65 mmHg) and low SVR.
Hemodynamic Profile: Produces intense arterial vasoconstriction, significantly increasing MAP, SVR, and systolic/diastolic blood pressure. The modest beta₁ stimulation increases stroke volume and myocardial contractility; however, reflex vagal bradycardia secondary to baroreceptor activation typically neutralizes direct beta₁ chronotropic effects, keeping heart rate relatively stable.
Dosing & Titration: Continuous IV infusion initiated at 0.01 to 0.05 mcg/kg/min (or 2 to 5 mcg/min) and titrated rapidly every 2–5 minutes to achieve target MAP ≥ 65 mmHg. Maximum standard titration ranges up to 3.0 mcg/kg/min (roughly 210 mcg/min in a 70 kg adult); many institutional protocols cap the weight-based rate far lower, around 0.5–1.0 mcg/kg/min (35–70 mcg/min), before adding a second agent.
Critical Nursing Considerations: Peripheral extravasation causes ischemic tissue necrosis. Acidosis (pH < 7.20) blunt receptor sensitivity, requiring higher infusion rates. Abrupt cessation can trigger profound rebound hypotension.
2. Epinephrine (Adrenalin)
Mechanism of Action: Potent, non-selective agonist at α₁, α₂, beta₁, and beta₂ adrenergic receptors.
Titration Dynamics & Receptor Selectivity:
Low Dose (0.01 to 0.05 mcg/kg/min): beta₁ and beta₂ adrenergic effects predominate. Produces robust positive inotropy, chronotropy, and enhanced cardiac output. SVR may remain unchanged or drop slightly due to beta₂-mediated vasodilation.
High Dose (>0.1 mcg/kg/min): α₁ adrenergic receptor stimulation overcomes beta₂ vasodilation, resulting in marked systemic arterial vasoconstriction, elevated SVR, and steep rises in MAP.
Clinical Indications: Severe cardiogenic shock refractory to dobutamine/norepinephrine, low cardiac output syndrome post-cardiac surgery, anaphylactic shock, and cardiac arrest resuscitation (1 mg IV push every 3–5 minutes).
Metabolic Effects & Adverse Profile: Stimulates skeletal muscle beta₂ receptors, activating Na+/K+ ATPase pumps and accelerating aerobic glycolysis to produce Type B hyperlactatemia (elevated serum lactate independent of tissue hypoperfusion). Induces severe hyperglycemia and carries high arrhythmogenicity (sinus tachycardia, atrial fibrillation, PVCs, ventricular tachycardia).
3. Dopamine
Mechanism of Action: Immediate metabolic precursor to norepinephrine. Displays a unique, tri-phasic dose-dependent receptor engagement spectrum.
Dose-Dependent Receptor Ranges:
Low Dose (0.5 to 3.0 mcg/kg/min): Stimulates vascular DA₁ receptors, dilating renal, splanchnic, coronary, and cerebral vascular beds. Clinical Pearl: AACN and KDIGO guidelines explicitly state that routine low-dose dopamine ("renal dose") is ineffective for preventing or treating acute kidney injury and should NOT be used.
Medium Dose (3.0 to 10.0 mcg/kg/min): Stimulates myocardial beta₁ receptors directly and promotes localized release of endogenous norepinephrine from cardiac sympathetic nerve terminals, boosting contractility, stroke volume, and cardiac output.
High Dose (10.0 to 20.0 mcg/kg/min): Overwhelmingly stimulates peripheral α₁ receptors, producing severe vasoconstriction and marked SVR elevation.
Limitations & Safety Warnings: Dopamine triggers significantly more tachyarrhythmias (atrial fibrillation, VT) and is associated with higher 28-day mortality in cardiogenic shock compared to norepinephrine (SOAP II trial).
4. Dobutamine
Mechanism of Action: Synthetic catecholamine operating as a potent, direct beta₁-adrenergic agonist with mild beta₂-adrenergic vasodilation and weak α₁ activity (beta₁ > beta₂ > α₁).
Clinical Indications: Primary inotrope choice for acute decompensated heart failure (ADHF) and cardiogenic shock with low cardiac index (CI < 2.0 L/min/m²) and elevated filling pressures (PCWP >18 mmHg) when systolic blood pressure is adequate (SBP > 90 mmHg).
Hemodynamic Profile: Increases stroke volume, cardiac index, and myocardial oxygen delivery while decreasing SVR, PVR, LVEDP, and PCWP. Reduces ventricular afterload, promoting forward ejection.
Dosing & Titration: IV infusion titrated from 2.5 to 20.0 mcg/kg/min.
Adverse Effects: Elevates MVO₂, causing myocardial ischemia in CAD. Induces tachyarrhythmias and can precipitate severe hypotension in hypovolemic patients.
5. Milrinone (Primacor)
Mechanism of Action: Selective Phosphodiesterase-3 (PDE-3) inhibitor. Prevents degradation of intracellular cAMP in cardiac myocytes and vascular smooth muscle cells.
Inodilator Properties: Elevates cAMP levels to enhance calcium influx during systole (positive inotropy) and accelerate calcium reuptake during diastole (positive lusitropy). In vascular smooth muscle, elevated cAMP causes potent systemic and pulmonary arterial vasodilation and venodilation (afterload and preload reduction).
Adrenergic Receptor Independence: Acts downstream of adrenergic receptors; remains fully effective in patients receiving chronic beta-blocker therapy (e.g., carvedilol, metoprolol).
Pharmacokinetics & Renal Elimination: Elimination half-life is 2.5 hours in normal renal function, extending to 4.0 to 6.0 hours in renal impairment. Excreted 85--90% unchanged by the kidneys. Mandatory dose reductions required for Creatinine Clearance (CrCl < 50 mL/min).
Dosing: Continuous IV infusion at 0.125 to 0.75 mcg/kg/min. Loading doses (50 mcg/kg over 10 min) are routinely omitted in CICU settings to prevent acute, severe hypotension.
6. Vasopressin (Argipressin / ADH)
Mechanism of Action: Direct non-adrenergic agonist at vascular V₁ₐ receptors. Activates Gq-PLC signaling to raise intracellular calcium in vascular smooth muscle cells.
Clinical Role: Second-line non-adrenergic vasopressor added to norepinephrine in septic shock (0.03 units/min fixed dose) or vasoplegic syndrome post-cardiopulmonary bypass (0.01 to 0.04 units/min).
Hemodynamic Advantages: Restores arterial tone in severe acidosis without causing tachyarrhythmias. Selectively constricts efferent renal arterioles, maintaining glomerular filtration rate (GFR) and urine output.
7. Extravasation Management & Nursing Interventions
Pathophysiology: Peripheral IV extravasation of α₁ vasopressors (norepinephrine, epinephrine, dopamine, phenylephrine) causes intense localized vasoconstriction, severe tissue ischemia, blanched cool skin, blistering, induration, and ischemic necrosis/sloughing.
AACN Nursing Extravasation Protocol:
Immediately stop the vasoactive infusion.
Do NOT remove the IV catheter immediately; attach a syringe and aspirate as much extravasated drug as possible from the cannula before removal.
Administer Phentolamine (Regitine) : A competitive non-selective α₁-adrenergic receptor antagonist. Dilute 5 to 10 mg of phentolamine in 10 to 15 mL of 0.9% sodium chloride. Using a fine-gauge (25–27G) needle, infiltrate small quantities subcutaneously in a circular pattern throughout the blanched, ischemic area within 12 hours of extravasation.
Elevate the extremity and apply warm compresses to promote localized blood flow.
Ensure all continuous vasoactive infusions are administered via dedicated central venous catheter (CVC) lumens with real-time continuous invasive arterial blood pressure monitoring.